文献速递神经肿瘤小儿神经外科与脑积水神经重症

分子靶向治疗后的肠壁积气

Pneumatosis Intestinalis After Molecular-Targeted Therapy.
PubMed 文献 · World Neurosurg · 2019-02-11

本文报告一例67岁男性转移性黑色素瘤、非小细胞肺癌及复发性小脑室管膜下瘤患者,因室管膜下瘤复发接受贝伐珠单抗治疗,随后出现肠壁积气。患者行脑室腹腔分流术后一周出现嗜睡及气腹,腹腔镜探查见局限性乙状结肠肠壁积气,无穿孔或缺血征象,停用贝伐珠单抗后影像学和临床改善。作者提出分子靶向治疗可能是神经外科患者气腹的潜在原因。

要点

  • 分子靶向治疗(MTT)在脑肿瘤治疗中应用增加,可能是神经外科患者气腹的潜在原因。
  • 接受MTT的肠壁积气患者可有良性体格检查,多数在停药后缓解。
  • 颅外操作后的气腹仍需排查和处理可能的肠穿孔,但也应考虑贝伐珠单抗等替代原因。

核心结论

  • 随着MTT在脑肿瘤管理中应用增加,作者提出MTT是神经外科患者气腹的潜在原因。
  • 颅外操作后的气腹仍需排查和处理可能的肠穿孔,但也应考虑贝伐珠单抗等替代原因。
  • 接受MTT的肠壁积气患者可有良性体格检查,多数在停药后缓解。

研究设计与样本

  • 病例报告:一例67岁男性转移性黑色素瘤、非小细胞肺癌及复发性小脑室管膜下瘤患者。

主要发现

  • 患者因室管膜下瘤复发开始贝伐珠单抗治疗,随后行脑室腹腔分流术,术后腹部X线片正常。
  • 分流术后一周患者嗜睡加重,CT显示纵隔气肿和气腹,因担心肠穿孔行诊断性腹腔镜并移除脑室腹腔分流管。
  • 术中见局限性乙状结肠肠壁积气,无肠穿孔或缺血征象。
  • 停用贝伐珠单抗后,患者影像学和临床表现改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumoperitoneum after surgical manipulation of the abdomen implies a perforation. Rare cases of nonoperated cancer patients, largely with gastrointestinal or genitourinary cancers, have been noted to have radiologic findings of pneumatosis intestinalis and/or pneumoperitoneum as a complication of molecular-targeted therapy (MTT) without confounding factors for perforation. We present a patient with a cranial malignancy treated with bevacizumab who subsequently manifested with pneumatosis intestinalis. CASE DESCRIPTION: A 67-year-old man with metastatic melanoma, non-small cell lung cancer, and recurrent cerebellar subependymoma was initiated on bevacizumab treatment for subependymoma recurrence. He subsequently underwent an uncomplicated ventriculoperitoneal shunt for progressive obstructive hydrocephalus, confirmed by a normal postoperative abdominal radiograph. One week later, he returned with worsening lethargy and a computed tomography consistent with pneumomediastinum and pneumoperitoneum. Due to concern for bowel perforation, the patient underwent diagnostic laparoscopy and removal of ventriculoperitoneal shunt. Focal sigmoid pneumatosis was identified without any signs of bowel perforation or ischemia. Bevacizumab was discontinued, and the patient's radiologic and clinical findings improved. CONCLUSIONS: With increasing utilization of MTTs in brain tumor management, we raise MTT as a potential cause for pneumoperitoneum in neurosurgical patients. Pneumoperitoneum after extracranial procedures still requires workup and management for potential bowel perforation, but alternative causes such as bevacizumab should also be considered. Pneumatosis intestinalis patients on MTT can have benign physical examinations and will resolve, in the majority of cases, on discontinuation of the drug.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Chaudhry NS, Bi WL, Gupta S, et al. Pneumatosis Intestinalis After Molecular-Targeted Therapy. World Neurosurg. 2019. PMID: 30763745. doi:10.1016/j.wneu.2019.01.225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。